PA at DPHARM 2024
17-18 September, Philadelphia
We’re excited to be speaking at The DPHARM Conference this year as our clinical trials transformation experts join hundreds of clinical innovation leaders to modernize clinical research.
This conference marks a pivotal time for the industry, when high costs, lengthy timelines, and complex regulatory environments are contrasted with innovative technologies, increased information and data, and growing patient engagement in trials.
Join us at this event to discuss overcoming clinical trial challenges with innovative, future-focused solutions that streamline processes and enhance outcomes.
Beyond the benchmarks: Setting new standards for speed in clinical trials
Tuesday 17 September 2024, 12:15pm-12:25pm (EDT)
Join us to explore the future of clinical development through the lens of advanced technology and human-centred innovation. Our experts will delve into tech-enabled collaboration, showcasing how AI-driven solutions break bottlenecks and accelerate development.
You’ll discover how to put people at the centre to streamline progress and meet stakeholder needs, learn about next-generation clinical research capabilities, and gain crucial insight into building adaptable technologies that redefine clinical trial standards. Don’t miss this opportunity to enhance the quality, efficiency, and speed of your clinical studies.
Clinical development expert
Charlie has a background in physics and extensive knowledge of lab technology, clinical trials design and execution, and provider operations. He drives the development and adoption of breakthrough technologies with leading organizations across the clinical trials continuum using data-driven approaches.
Clinical development expert
Kelsey has an established track record of leading and managing transformation in pharmaceutical R&D. She has advised Top 20 BioPharma and industry consortia on clinical innovation, new service and business model development, R&D technology strategy, digital transformation, improving the patient experience, and leveraging novel data sources across preclinical, clinical, and drug safety.
Featured insight
